Introduction
============

The effects of 17β-estradiol (E~2~) are mediated through binding to the estrogen receptor α (ERα) and estrogen receptor β (ERβ) nuclear receptor transcription factors. Upon ligand binding, the receptor dimerizes and recruits coregulator proteins. The receptor-coregulator complex binds to specific DNA sequences within the promoter regions of ER-regulated genes to regulate gene transcription \[[@r9]\]. Other ligands elicit different effects on receptor dimerization, coregulator recruitment and DNA binding.

The importance of ERα in human physiology and breast cancer has been clearly demonstrated. However, the role of ERβ in breast cancer has only recently become more evident. For example, the ERα/ERβ ratio may be altered during carcinogenesis such that ERα expression proportionally increases as cells progress to malignancy \[[@r7]; [@r14]\]. Co-expression of ERα and ERβ and treatment with tamoxifen increases the antagonistic effect in an ERβ dose-dependent manner, suggesting that ERβ is a negative regulator of ERα action \[[@r14]; [@r19]\]. ERα and ERβ may bind as hetero- or homo-dimers at ERE-containing promoters \[[@r6]; [@r18]; [@r26]; [@r27]\]. The preferential dimerization between ERs may be key to understanding the mechanisms regulating either tamoxifen agonist or antagonist activity.

Most studies that examine nuclear receptor interactions have employed artificial reporter gene assays and co-immunoprecipitation with inherent limitations. Studies on truncated estrogen receptor and/or coregulator protein-protein interactions has been shown by several *in vitro* mechanisms \[[@r6]; [@r8]; [@r20]; [@r29]\] as well as *in vivo* assays using fluorescently labeled fusion proteins such as fluorescence resonance energy transfer (FRET) and fluorescence recovery after photobleaching (FRAP) \[[@r1]; [@r25]; [@r26]\]. A major challenge to understanding receptor dimerization and coregulator recruitment *in vivo* is the development of robust methods that; 1) accurately measure protein-protein interactions in real time in live cells; 2) exhibit specificity and low background; 3) can identify effects of posttranslational modifications on interactions. The application of BRET^2^ addresses these critical requirements.

BRET^2^ is characterized by the efficient transfer of excited energy between a bioluminescent donor molecule (*Renilla* luciferase) and a fluorescent acceptor molecule (a mutant of Green Fluorescent Protein). The BRET^2^ assay has advantages over FRET analysis because it does not require an external light source, thereby eliminating the problems of photobleaching and autoflourescence. The absence of contamination by light results in a low background that allows detection of very small changes in the BRET^2^ signal. BRET^2^ is dependent on the orientation and distance between two fusion proteins and therefore requires preliminary standardization experiments to conclude a positive BRET^2^ signal, independent of variations in protein titrations and arrangement in tertiary structures.

Resonance energy transfer has become an invaluable mechanism for the quantitative analysis of the transient protein-protein interactions of hormone receptors. An excellent review by Eidne et al. \[[@r10]\] describes application of the various methods of resonance energy transfer to study dynamic hormone receptor interactions within living cells. The predominant use of BRET^2^ technology to date has been to measure membrane receptor interactions, including quantitative analysis of hetero- and homo-dimerization and subsequent signaling pathways of G-protein coupled receptors \[[@r3]; [@r13]; [@r15]; [@r16]; [@r22]; [@r28]\], as well as confirming interactions between growth factor receptors such as IGF-1, TGF-βRII, and FGF with novel proteins \[[@r4]; [@r5]; [@r23]\]. To date, there are few published articles utilizing BRET technology in nuclear receptor interactions. Utilizing BRET^2^, Garside at al. found that the glucocorticoid receptor (GR) antagonist RU486 efficiently recruited the nuclear corepressor NCoR to the GR, whereas dexamethasone recruited SRC-1 \[[@r12]\]. More recently, Michelini et al. were the first to demonstrate that BRET^2^ can evaluate estrogen receptor homodimerization \[[@r17]\].

In this study we have extensively explored BRET^2^ technology to define its use and limitations as a novel approach to study steroid receptor protein-protein interactions.

Reagents and instruments
========================

Plasmid construction
--------------------

The human pGFP^2^-C, pGFP^2^-N, pRluc(h)-C, and pRluc(h)-N terminal expression vectors were purchased from Perkin-Elmer Life Sciences. The GFP^2^-N-ERα, Rluc-N-SRC-1, and Rluc-C-SRC-1 fusion proteins were constructed by amplifying the estrogen receptor and SRC-1 fragments from the pCR3.1 vector by PCR and digesting the KpnI and ApaI sites of both the PCR products and the expression vectors. The GFP^2^-C-ERα fusion protein was constructed by amplifying the estrogen receptor by PCR and digesting the BamHI and BspEI sites of the insert as well as the expression vector. All constructs were verified by direct DNA sequencing.

Western blotting
----------------

HEK-293 cells (ATCC) were cultured and maintained in DMEM supplemented with 10% FBS, l-glutamine, and antibiotics at 37°C, 95% O~2~, and 5% CO~2~. Cells (3x10^6^) were seeded in 10-cm dishes and transfected with 10µg each of the above expression vectors using Lipofectamine 2000 transfection reagent (Invitrogen). 24 hours post-transfection, cells were rinsed with cold PBS, scraped from the plates and the cell pellet was lysed in 400μl of lysis buffer containing 50mM Tris-HCl (pH 7.5), 420mM NaCl, 1% NP-40, and supplemented with a protease inhibitor cocktail (Sigma). The cell lysate was centrifuged at 15,000 x g at 4°C for 20 minutes. The protein concentration in the supernatant was determined and 50μg of protein lysate was boiled in Laemmli loading buffer and subjected to a 10% SDS-PAGE for Western blotting with antibodies to ERα (VPE-614, Vector Laboratories, Burlingame, CA), GFP (SC9996, Santa Cruz Biotechnology, Santa Cruz, CA) or Rluc (MAB4400, Chemicon, Temecula, CA).

Co-immunoprecipitations
-----------------------

HEK-293 cells were cultured and transfected as described above. Cells (3x10^6^) were transfected with 10μg of Rluc-C-SRC-1 and 10μg GFP^2^-C-ERα or vector. 48 hours post-transfection, cells were rinsed in cold PBS, scraped from the dishes and the cell pellet was lysed in 400μl of hypotonic lysis buffer (20mM HEPES pH 7.5, 10% glycerol, 1mM PMSF) using five strokes of a dounce homogenizer. The lysate was centrifuged at 1,000 x g at 4°C for 20 minutes to pellet the nuclei. The cytosolic supernatant was removed and set aside at 4°C. The volume of the packed nuclei (Packed Cell Volume, or PCV) was determined and low-salt NP-40 lysis buffer (20mM HEPES pH7.5, 150mM NaCl, 1% NP-40, 50mM Tris-HCl pH 7.5, 1mM PMSF) was added at twice the PCV. The nuclear pellet was vortexed at 5 minute intervals for 30 minutes at 4°C, then centrifuged at 15,000 x g for 10 minutes at 4°C. The nuclear extract was combined with the cytosolic extract and the protein concentration was determined. Separating the cytosolic and nuclear extracts in this manner was found to preserve the protein-protein interactions and increase the yield. 500μg of combined cell lysate was pre-cleared by incubation with Protein A agarose beads for 30 minutes at 4°C. The pre-cleared supernatant was then incubated with SRC-1 antibody (0.5µg/100µg lysate; M-341, Santa Cruz) rotating overnight at 4°C. 20µl of Protein A agarose beads were added and the solution and incubated for 1 hour at 4°C while rotating. The resulting protein A/immunocomplex was then centrifuged at 15,000 x g for 1 minute at 4°C, washed in low-salt NP-40 lysis buffer, and repeated 3x. The beads were boiled in Laemmli loading buffer for 10 minutes and followed by electrophoresis by 10% SDS-PAGE.

Luciferase assays
-----------------

HeLa cells were cultured in phenol-red free DMEM with 5% fetal bovine serum and plated in 6-well dishes at a confluency of 2x10^5^ cells/well. The medium was replaced with medium containing 2% dextran-coated charcoal-stripped serum and the cells were incubated for 48 hours. Cells were then transfected with 500ng of EREe1b-luciferase reporter using Fugene6 transfection reagent. 24 hours post-transfection, cells were incubated with vehicle or 10^-8^ M estradiol for 24 hours. The cells were lysed with luciferase lysis buffer and centrifuged at 20,000 x g at room temperature for 5 min. to remove cellular debris. The supernatant was used for a standard luciferase assay using a luminometer and luciferase assay values were normalized to protein measured by Bradford assay.

Bioluminescence Resonance Energy Transfer (BRET^2^)
---------------------------------------------------

HEK-293 cells were plated in 6-well plates (200,000 cells/well) and incubated in medium containing 5% charcoal-stripped serum overnight. Cells were transfected with varying amounts of the BRET^2^ expression vectors using Lipofectamine 2000 (Invitrogen) transfection reagent. 48 hours post-transfection, the cells were harvested and washed 2x in BRET Buffer (PBS plus 2μg/ml aprotinin). 50,000 cells in 40μl buffer were incubated with vehicle or 10^-8^M estradiol for 30 minutes at room temperature in 96-well white Optiplates (PerkinElmer). Following addition of 5μM DeepBlueC substrate, luminescence and fluorescence emissions were measured immediately on the Packard Fusion instrument at 410nm and 515nm, respectively. An extensively detailed protocol for BRET^2^ follows.

Methods
=======

Since BRET^2^ requires transfection of fusion proteins, receptor negative cell lines that exhibit high transfection efficiency should be used. Standardization experiments must be performed before assaying fusion proteins of interest. We suggest using known interacting proteins and their respective agonists as a positive control when first applying BRET^2^ methodology. We found HEK-293 cells, in which most reported data with BRET^2^ has been documented, exhibited the highest transfection efficiency and protein expression for the very large coactivator fusion proteins used in this study. Consequently, HEK-293 cells yielded the most robust BRET^2^ signal when assessing ERα interactions. To assess functionality of the ERα and SRC-1 fusion proteins, HeLa cells were used. Although transfection efficiency, fusion protein expression and consequently BRET^2^ signal was reduced in HeLa compared to HEK-293 cells, HeLa cells are well characterized for response to estradiol in reporter gene assays and recruitment of coregulators and are therefore deemed most appropriate to confirm the functionality of the fusion proteins in comparison to wild-type proteins. The protocol detailed below is adapted from the PerkinElmer technical data sheet for catalog number 6310556, Appendix A (www.perkinelmer.com).

Preliminary experiments
-----------------------

1\. Create a minimum of four fusion protein vectors for each protein to test whether differences in protein folding and post-translational modifications may contribute to the interaction. The orientation of the BRET^2^ tag can also effect protein expression and function. GFP^2^ and Rluc fusion construct combinations are shown in [Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"}.

2\. Verify the functionality and expression of all combinations of fusion proteins. Expression can be assayed by immunoblot, and the functionality of each nuclear receptor fusion protein can be confirmed with a standard reporter gene assay in which the reporter contains the hormone responsive element for the nuclear receptor. Quantitative expression of each fusion protein can also be tested individually by the Fusion instrument. Testing the expression of each bioluminescent/fluorescent fusion protein signal separately will provide the user with the maximum level of fluorescence/luminescence output without resonance energy transfer.

\- For the GFP^2^ signal: In a 96-well black Optiplate, aliquot 50,000 transfected cells/well (25μl) and add 175μl BRET^2^ buffer. Read on the Fusion instrument (Fluorescence mode). (PMT:1000 volts, Gain:1, read time 0.5 sec, excitation 425/20, emission 515/30).

\- For the Rluc signal: In a 96-well white Optiplate, aliquot 50,000 cells/well (25μl) and add 150μl BRET^2^ buffer. Add 50μl of 20μM coelentrazine h (5μM final). Incubate covered with foil 18 minutes. Read on the Fusion instrument (Luminescence mode). (PMT:900, Gain:1, read time 1 sec, emission 410).

BRET^2^ assay
-------------

The optimal amount of each fusion protein construct used in co-transfection experiments depends on factors such as the affinity of the two interacting domains and the levels at which each construct is expressed. For this reason, a simple 1:1 ratio of DNA may not yield the best results. Therefore, a transfection matrix experiment must be performed with various ratios of each construct and used for BRET^2^ measurements. [Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"} shows an example of a BRET^2^ transfection matrix.

1\. Transfect HEK-293 cells in 100mm dishes with combinations of DNA listed above using Lipofectamine 2000 according to the manufacturer's instructions. Use GFP^2^ vector (without insert) when transfecting the Rluc-Protein B to keep the DNA concentration constant (Conditions 2, 7, and 12).

2\. BRET^2^ assays can be performed 24-72 hours post-transfection depending on protein turnover and cell doubling-time. At the time of the assay, wash cells in BRET^2^ buffer (Dulbecco's Phosphate Buffered Saline (D-PBS) containing CaCl2 (0.1g/l), MgCl2 (0.1g/l), and D-Glucose (1g/l) supplemented with Aprotinin (2μg/ml)) twice, and harvest in BRET^2^ buffer.

3\. Count the cells and resuspend 1x10^6^/ml in BRET^2^ buffer. Aliquot 50μl (50,000) cells in triplicate into a 96-well white Optiplate. This constitutes the non-treated cells. Aliquot another 50μl cells in triplicate for each ligand.

4\. Add ligand (diluted in BRET^2^ buffer) or buffer alone to each well. Incubate at room temperature for 30 minutes. For example, add 6μl of a 1μM dilution of Estradiol for a final concentration of 10nM (56μl total).

5\. Start BRET^2^ reaction by adding 14μl of 25μM (5μM final) DeepBlueC substrate one column at a time (70μl total volume). Read each column immediately on the Fusion instrument before addition of substrate to the next column.

6\. Immediately following addition of DeepBlueC, read the plate on a Fusion microplate analyzer with the following settings: one second per well, PMT: 1100 volts and gain: 100, using the following 410/515 nm filter pairs: a) Rluc emission: 410 nm bandpass 80 nm; b) GFP^2^ emission: 515 nm bandpass 30 nm.

BRET^2^ can be further optimized by altering the number of cells assayed. After determining the greatest difference in signal to background from the transfection matrix (see data analysis), titrate the number of cells (50,000 to 200,000) from that particular ratio. The number of cells per well depends on protein expression levels and transfection efficiencies (i.e., the lower the protein expression, the higher the number of cells required). For each co-transfection, it is also necessary to assay Rluc-Protein B co-transfected with the empty GFP^2^ vector, and untransfected cells alone for calculation purposes (see below). For example, if Condition 3 (a co-transfection of both GFP^2^-Protein A and Rluc-Protein B) yield the highest BRET^2^ signal, one must simultaneously assay the same amount of Rluc-Protein B expressed with the empty GFP^2^ vector (Condition 2), as well as assay untransfected cells (Condition 1).

7\. Resuspend cells in varying concentrations (1x10^6^/ml to 4x10^6^/ml) and aliquot 50μl of cells in triplicate per concentration. An example of a 96-well Optiplate is shown under "Cell number titration" in [Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"}.

8\. Follow with steps 6-8 for BRET^2^ analysis.

Data analysis
-------------

The average counts obtained between the triplicate wells with non-transfected cells (treated or untreated with ligand) are subtracted from the reading of transfected cells in each well (with or without ligand, respectively) to obtain the corrected counts at both wavelengths. Using the corrected counts, the BRET^2^ signal is then determined as the ratio between GFP^2^ emission (515 nm) and Rluc emission (410 nm). This is illustrated in Calculation \#1, [Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"}. (When subtraction of the background counts yields negative values, a BRET^2^ ratio of zero is assigned.)

There are two calculations to analyze the BRET^2^ ratio ([Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"}). Both are independent and derived from the basic dogmatic principle of resonance energy transfer; GFP^2^ emission/Rluc emission. Both are correct and either can be used depending on presentation of data. Calculation \#1 ([Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"}) is best for presenting ligand-dependent versus ligand-independent interactions because it simply subtracts raw background emission from itself. In the assay above, subtract the fluorescence signal of Condition 1 (non-transfected) by the fluorescence signal of Condition 3 (GFP^2^-Protein A and Rluc-Protein B co-transfection) divided by the luminescence signal of Condition 1 subtracted by the luminescence signal of Condition 3.

Calculation \#2 ([Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"}) is the corrected BRET^2^ ratio (Calculation \#1) and subtracts the correction factor. The correction factor is the corrected fluorescent/luminescent signal for the Rluc-Protein B expressed with the empty GFP^2^ vector. Instead of visualizing basal interactions as with Calculation \#1, it incorporates possible false positive resonance energy transfer signals due to forced interactions between over-expressed Rluc or GFP^2^ fusion proteins. This calculation is best for comparing time-course or multiple ligands in one graph. In the assay described above, use Calculation \#1 to calculate the corrected BRET^2^ ratio of both the Rluc-Protein B expressed with the empty GFP^2^ vector (Condition 2, or Cf), and the GFP^2^-Protein A:Rluc-Protein B co-transfection (Condition 3). Then subtract corrected Condition 2 from the corrected Condition 3.

Results
=======

We have used the well characterized examples of estradiol-dependent dimerization of ERα and estradiol-dependent recruitment of the coactivator SRC-1 to demonstrate application of BRET^2^. The following data obtained using BRET^2^ technology is consistent with previously reported data using other methodologies and establishes BRET^2^ as a viable methodology to measure well characterized estrogen receptor functions.

Expression of GFP^2^-C and -N terminal estrogen receptor and Rluc-C-SRC-1 fusion proteins
-----------------------------------------------------------------------------------------

[Figure 1](#fig1){ref-type="fig"}A-C shows the expression of the GFP^2^-C and -N terminal estrogen receptor and Rluc-C-SRC-1 fusion proteins by Western analysis in the ER negative human cervical carcinoma cell line, HeLa. [Figure 1](#fig1){ref-type="fig"}D-E demonstrates the transfection efficiency of the GFP^2^-Rluc positive control vector at 24 hours post-transfection in HEK-293 cells. Wild-type ER is 66kD molecular weight. Based on primary sequence, the predicted molecular weights of the GFP^2^-ERα, Rluc-ERα and Rluc-SRC-1 constructs are 93kD, 100kD, and 195kD, respectively and Western blot signals corresponding to these sizes are detected ([Figure 1](#fig1){ref-type="fig"}). Other bands evident on the Western blots are the results of either non-specific antibody signal ([Figure 1](#fig1){ref-type="fig"}C, all lanes) and/or partial protein degradation during lysis ([Figure 1](#fig1){ref-type="fig"}A).

Functional analysis of N- and C-terminal fusion proteins of ERα and SRC-1
-------------------------------------------------------------------------

[Figure 2](#fig2){ref-type="fig"} demonstrates the functionality of the ERα and SRC-1 fusion proteins by transient co-transfection with the ERE~2~e1b-luciferase reporter plasmid in ER-negative HeLa cells followed by standard luciferase assays. All combinations of N- and C- terminal SRC-1 fusion proteins potentiated GFP^2^-ERα activation of the reporter ([Figure 2](#fig2){ref-type="fig"} A, B, D) with the exception of the combination of GFP^2^-N-ERα and Rluc-C-SRC-1 ([Figure 2](#fig2){ref-type="fig"}C). One possible reason for the absence of coactivation by this combination may be interference of the fluorescent tags with receptor-coactivator interaction. Direct comparison between the fusion proteins with wild type ERα and SRC-1 confirmed that the fusion proteins had comparable activity to wild type proteins in estradiol activation and coactivation of the ERE~2~e1b-luciferase reporter ([Figure 2](#fig2){ref-type="fig"}E-F). It is important to note that expression of Rluc fusion proteins may contribute to the luciferase reporter gene assay. Luciferase assays may also be used to measure expression of the fusion protein in cells. Although expression of Rluc-C-SRC-1 did not appear to contribute significantly to the luciferase assays in [Figure 2](#fig2){ref-type="fig"}, the investigator must recognize this caveat when luciferase reporter gene assays are used to measure the functionality of Rluc fusion proteins.

ERα homodimers demonstrated by the BRET^2^ assay
------------------------------------------------

To first determine the dose of estradiol required to stimulate homodimerization as assessed by BRET^2^ in HEK-293 cells, an agonist dose response curve was generated. Estradiol stimulated ER homodimerization in a dose dependent manner (data not shown). We assessed estradiol-dependent homodimerization by BRET^2^ using different combinations of GFP^2^ and Rluc, C- and N- terminal ERα fusions. By titration of GFP^2^-ERα and Rluc-ERα expression vectors it was determined that transfection of 10μg of both the GFP^2^-ERα and the Rluc-ERα fusion vectors resulted in the maximum estradiol-dependent dimerization as assessed by BRET^2^. All combinations of C- and N-terminal ERα fusion proteins exhibited homodimerization in response to estradiol ([Figure 3](#fig3){ref-type="fig"}A). The maximum observed BRET^2^ ratio occurred when using the GFP^2^-N-ERα, and Rluc-C-ERα fusion proteins ([Figure 3](#fig3){ref-type="fig"}A). In [Figure 3](#fig3){ref-type="fig"}B, the dashed line represents background BRET^2^ signal assessed from cells co-transfected with Rluc-C-ERα and the GFP^2^ vector. This negative control accounts for any false-positive BRET^2^ signals due to protein over-expression. In addition to estradiol induced homodimerization, we also observed ligand-independent homodimerization of ERα ([Figure 3](#fig3){ref-type="fig"}B, bar 3). Estradiol induced GFP^2^-C-ERα and Rluc-C-ERα homodimerization within 30 minutes (data not shown) and continued to stimulate this interaction for up to 12 hours ([Figure 4](#fig4){ref-type="fig"}A). To confirm the dimerization identified by BRET^2^, HEK-293 cells cotransfected with GFP^2^-C-ERα and Rluc C-ERα were coimmunoprecipitated with an antibody to GFP and probed by Western blot with antibody to Rluc ([Figure 4](#fig4){ref-type="fig"}B).

Interaction of ERα and the nuclear coactivator SRC-1 demonstrated by the BRET^2^
--------------------------------------------------------------------------------

[Figure 5](#fig5){ref-type="fig"} demonstrates the estradiol-dependent interaction of ERα and SRC-1 by titration of the GFP^2^-C-ERα and Rluc-C-SRC-1 fusion proteins as assessed by BRET^2^. The maximum BRET^2^ signal was approximately two-fold compared to basal interaction and occurred at 10μg of both GFP^2^-C-ERα and Rluc-C-SRC-1. The basal BRET^2^ signal is represented by the Rluc-C-SRC-1 fusion protein expressed without the estrogen receptor ([Figure 5](#fig5){ref-type="fig"}A). Estradiol induced interaction between GFP^2^-C-ERα and Rluc-C-SRC-1 within 1 hour and continued to stimulate this interaction for up to 12 hours ([Figure 5](#fig5){ref-type="fig"}B). The estradiol-dependent interaction between GFP^2^-C-ERα and Rluc-C-SRC-1 was confirmed by co-immunopreciptation (data not shown). Interestingly, in the absence of ligand there was a decrease in the BRET^2^ ratio over time when measuring ERα/SRC-1 interaction, but not ERα dimerization. It is possible that the interaction between ERα and SRC-1 in the absence of ligand may be cyclical or sporadic. This possibility is currently under investigation.

Discussion
==========

We demonstrate the use of BRET^2^ to assess *in vivo* protein interactions between nuclear receptors and coregulators in real-time. To establish BRET in a ligand inducible system, we chose to use the nuclear coactivator SRC-1 as the donor moiety, and the estrogen receptor as the acceptor moiety. Functionality of these fusion proteins was assessed by transient transfection in HeLa cells, followed by Western blot analysis for protein expression and reporter gene activity. Titration of ER and SRC-1 protein levels was needed to obtain an accurate molar ratio of the Rluc and GFP^2^ fusion proteins needed for BRET.

Published work with BRET^2^ does not contain standardization experiments that are imperative to conclude a positive BRET^2^ signal for data interpretation. Although BRET^2^ is a sensitive assay for assessing ligand and time dependent changes in nuclear receptor interactions in live cells, one limitation of BRET^2^ is that it is not quantitative. This is because ligand-induced conformational changes of the receptor may place the GFP^2^ moiety too distant from the Rluc moiety for efficient resonance energy transfer. Consequently, a large increase in the BRET^2^ ratio may not necessarily indicate a quantitatively greater interaction between proteins than smaller increases in the BRET^2^ ratio.

The functionality of the fusion proteins must be confirmed prior to assessing protein interactions by BRET^2^. Once the function of the fusion proteins are confirmed, titrations of the transfected expression constructs must also be performed to exclude background and insignificant BRET signals. Background BRET^2^ signal is defined as the fluorescent/luminescent quantitative number measured by the Fusion instrument for untransfected cells. An insignificant BRET^2^ signal is a signal that can occur by overexpression of the fusion proteins. Nuclear receptor function may also be assessed by other common approaches such as ligand binding, DNA binding, subcellular localization, and measuring endogenous receptor-regulated gene expression. Coactivator functionality is commonly assessed by their ability to enhance the transcriptional activity of steroid receptors. The ERα negative human embryonic kidney cell line HEK-293 is especially amenable to BRET^2^ analysis (see description of BRET^2^ at www.perkinelmer.com). Using only the ER ligand-binding domain instead of full-length receptor, previous reports using FRET demonstrated that dimerization is estradiol dose-dependent \[[@r1]; [@r26]\]. We show not only full-length estrogen receptor homodimerization, but also ERα interaction with the coactivator SRC-1, is dose-dependent, induced within thirty minutes, and stable over a twelve-hour time period.

Application of BRET^2^ for studying nuclear receptor interactions
-----------------------------------------------------------------

BRET^2^ is an excellent method for measuring nuclear receptor interactions with other proteins as a consequence of specific ligand binding, receptor mutations and posttranslational modifications in a time-dependent manner. For example, this study, which demonstrates and validates BRET^2^ for nuclear receptor interactions, uses full-length estrogen receptor and estradiol dependent receptor dimerization and recruitment of coactivator SRC-1. A simple extension of this study to include existing or novel ligands for ER would yield time dependent data comparing receptor homodimerization and SRC-1 recruitment. In this manner, BRET^2^ would become especially useful in comparing activity of novel SERMs. Through preparation of fusion constructs for ERβ and other coregulators, information about additional nuclear receptor interactions could be obtained. Nuclear receptor posttranslational modifications such as phosphorylation, acetylation, and sumoylation among others play an important role in protein-protein interactions \[[@r11]; [@r21]; [@r24]\]. Receptor posttranslational modifications in response to subcellular localization, ligands, drugs, or peptide hormone signaling pathways impacts nuclear receptor-dependent gene transcription and can regulate the relative agonist/antagonist properties of mixed ligands. Using the example of receptor phosphorylation, BRET^2^ technology can measure the precise contribution of single and multiple receptor phosphorylation sites to dimerization, coregulator recruitment and interactions with other proteins through preparation of point mutations in the receptor GFP- or Rluc-fusion proteins.

Supplementary Material
======================
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Figures and Tables
==================

![Expression of the GFP^2^-C and -N terminal estrogen receptor and Rluc-C-SRC-1 fusion proteins assessed by Western blot analysis\
HeLa cells were plated in 10-cm dishes and transfected with 5µg each of the above expression vectors. 100µg of total cell extract was prepared for 8% SDS-PAGE and Western blotting with antibody to hERα (A and B), or Rluc (C). Transfection efficiency of the GFP^2^-Rluc positive control vector at 24 hours post-transfection in phase contrast (E) or the overlay of the phase contrast on the GFP filter (F) on a fluorescent microscope.](nrs04021.f1){#fig1}

![Fusion of GFP^2^ or Rluc to ERα and SRC-1 does not alter protein function\
HeLa cells were transfected with 100ng of GFP^2^-C-ERα (A and B) or GFP^2^-N-ERα (C and D) expression vector with increasing amounts (100, 200, 400, 600, 800, 1000 ng) of either Rluc-C-SRC-1 (A and C) or Rluc-N-SRC-1 (B and D) expression vector, and 500ng of ERE-luciferase reporter, and the remaining amount of DNA with a vector containing a CMV promoter. The DNA levels were equivalent, with 1600ng of total transfected DNA. To confirm that the fusion proteins had comparable activity to wild type proteins, cells were transfected with reporter gene and 100ng of GFP^2^-C-ERα or WT-ERα to compare ERα activity (E) or with 100ng of GFP^2^-C-ERα + 500 ng of Rluc-C-SRC-1 or WT-SRC-1 to compare SRC-1 activity (F). All cells (A-F) were incubated with either vehicle or 10^-8^M estradiol for 24 hours. The cells were lysed and luciferase expression was measured by a luminometer.](nrs04021.f2){#fig2}

![17β-estradiol induced homo-dimerization of the ERα as assessed by BRET^2^\
HEK-293 cells were transiently co-expressed with the GFP^2^-C-ERα (40µg) and Rluc-C-ERα (10µg) fusion proteins to generate a dose-response curve with estradiol treatment (data not shown). The estradiol-induced interaction by BRET^2^ occurs between all combinations of ERα fusion proteins, regardless of differences in tertiary structure. HEK-293 cells were transfected with 10µg each of a GFP^2^-ERα and Rluc-ERα fusion protein and incubated with vehicle or 10^-8^ M estradiol for 30 minutes (A). Luminescence and fluorescence emissions were then read immediately following addition of DeepBlueC substrate for the BRET^2^ assay. To determine the ligand-dependent and -independent homodimerization of ERα, HEK-293 were transfected with 10µg of Rluc-C-ERα and 10µg of either GFP^2^-C-ERα or the GFP^2^-C vector alone and treated for 30 minutes with 10^-8^M estradiol (B). The ligand-dependent and -independent BRET^2^ interaction of GFP^2^-C-ERα and Rluc-C-ERα with and without estradiol treatment is indicated by bars above the dashed line. The dashed line represents basal activity. This figure is representative of five experiments.](nrs04021.f3){#fig3}

![Time course for ligand-dependent ERα homodimerization as assessed by BRET^2^\
HEK-293 cells were co-transfected with Rluc-C-ERα and either GFP^2^-C-ERα or the GFP^2^ vector alone. The cells were incubated with vehicle (DMSO) or 10^-8^M estradiol (E~2~). The BRET^2^ assay was performed at a time course of 1, 4, 8, and 12 hours (A). The BRET^2^ signal was performed in triplicate and repeated three times. Co-immunoprecipitation confirms estradiol-induced homodimerization between GFP^2^-C-ERα and Rluc-C-ERα (B). HEK-293 cells were untransfected (Lane 1) or transfected with 10µg each of Rluc-C-ERα and 10µg of GFP^2^-C vector (Lane 3), and incubated with 10^-8^M estradiol. Immunoprecipitated Protein A agarose beads without antibody was used as a control (Lane 2). Whole cell lysate was immunoprecipitated with ERα antibody followed by Western blot for ERα. The molecular weight of Rluc-C-ERα is 101kD.](nrs04021.f4){#fig4}

![Ligand-dependent interaction between GFP^2^-C-ERα and Rluc-C-SRC-1 as assessed by BRET^2^\
(A) HEK-293 were transfected with 10μg of Rluc-C-SRC-1 and 10µg of either GFP^2^-C-ERα or the GFP^2^-C vector alone and incubated for 30 minutes with 10^-8^M estradiol. The ligand-dependent interaction of GFP^2^-C-ERα and Rluc-C-SRC-1 in the presence of estradiol treatment is indicated by the bar above the dashed line. The dashed line represents basal activity. (B) Time course for ligand dependent interaction between ERα and SRC-1. HEK-293 cells were incubated with vehicle (DMSO) or 10^-8^M estradiol (E~2~). Figure is representative of five experiments.](nrs04021.f5){#fig5}
